Gene editing has very rapidly established its importance as a research and screening tool in drug discovery, and promises its utility downstream in drug development, cell therapy and bioprocessing, as well. Cambridge Healthtech Institute’s third annual conference on CRISPR-Based Genome Editing - Part 2 will bring together experts from all aspects of preclinical, translational and clinical research to discuss the progress being made in gene editing, and how and where it’s being applied. Knowing the strengths and limitations, how does one decide when to use the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system, as opposed to other genome editing systems? What is being done to overcome some of the inherent challenges in design, delivery and off-target effects, associated with CRISPR and some of its alternatives that are being developed? Experts from pharma/biotech, academic and government labs will share their experiences leveraging the utility of some of the new gene editing tools being developed for diverse applications including creating cell lines and knock-out models, for functional screening, cellular pathway visualization, and for therapeutics.